# Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction

> **NCT05184192** · PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 68 (actual)

## Conditions studied

- COVID-19
- Olfactory Disorder
- Anosmia
- Hyposmia
- Parosmia

## Interventions

- **DRUG:** Gabapentin gelatin capsules 300mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05184192
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-10
- **Primary completion:** 2023-08-29
- **Final completion:** 2023-08-29
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2025-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05184192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05184192, "Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05184192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*